May 19, 2014 — St. Jude Medical announced that data presented during a late-breaking clinical trial session at the 2014 annual scientific sessions of the Heart Rhythm Society (HRS) found an association between adherence to remote monitoring with the Merlin remote monitoring system and a reduction in patient mortality. Results from more than 260,000 patients implanted with either pacemakers or defibrillators demonstrated that patients with high adherence to remote monitoring had more than twice (2.4x) the probability of survival than that of patients without remote monitoring.
The prospective, observational study of U.S. patients also found that the greater the adherence to remote monitoring, the better the patient fared. Patients with high adherence to remote monitoring — measured as weekly transmission of patient data from the Merlin@Home System to the Merlin.net patient care network at least 75 percent of the time — overall had a 58 percent reduced likelihood of mortality than patients not using remote monitoring and a 35 percent reduced likelihood of mortality than patients with low remote monitoring. Though there was geographic variability, socioeconomic factors were not associated with remote monitoring use.
“This study is the first of its kind to find increased survival when remote monitoring is utilized in pacemaker patients,” said Suneet Mittal, M.D., director of EP at the Valley Hospital Health System of N.Y. and N.J. “Furthermore, our data suggest that, irrespective of whether a patient has a pacemaker or defibrillator, higher use of remote monitoring is associated with better survival. Although these associations require further investigation, these important observations should have significant implications for individual patient care and best-practice guidelines.”
All St. Jude Medical U.S. Food and Drug Administration (FDA) approved implantable cardiac devices capable of radiofrequency (RF) remote monitoring were included in the study, which had a cohort of 262,564. This is the largest study to date of remote monitoring pacemaker patients, and one of the largest for remote monitoring overall.
“Patients with implanted cardiac devices are typically required to visit doctors’ offices several times per year to have their device performance checked, which for many can be impractical. This new research demonstrates that the Merlin patient care system not only adds convenience for physicians and patients, it helps patients to live longer,” said Mark D. Carlson, M.D., chief medical officer for St. Jude Medical.
For more information: www.sjm.com
November 18, 2024 
